Avenue Therapeutics, Inc. (ATXI) stock
ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.43+0.00 (0.00%)
Close on Oct 16, 2026Market cap $1.42MP/E –Yield –
Avenue Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Avenue Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $881.00K, down 74.8% year over year. For fiscal 2025 it was $1.04M, down 84.4% from the year before. The highest annual figure on record is $22.19M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04M | -84.4% |
| FY2024 | Dec 31, 2024 | $6.65M | +8.4% |
| FY2023 | Dec 31, 2023 | $6.13M | +127.2% |
| FY2022 | Dec 31, 2022 | $2.70M | +115.2% |
| FY2021 | Dec 31, 2021 | $1.25M | -56.2% |
| FY2020 | Dec 31, 2020 | $2.87M | -87.1% |
| FY2019 | Dec 31, 2019 | $22.19M | +25.4% |
| FY2018 | Dec 31, 2018 | $17.70M | +164.2% |
| FY2017 | Dec 31, 2017 | $6.70M | +403.2% |
| FY2016 | Dec 31, 2016 | $1.33M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $247.00K | +28.6% |
| Q1 FY2026 | Mar 31, 2026 | $200.00K | -51.3% |
| Q4 FY2025 | Dec 31, 2025 | $257.00K | -54.5% |
| Q3 FY2025 | Sep 30, 2025 | $177.00K | -92.4% |
| Q2 FY2025 | Jun 30, 2025 | $192.00K | -85.9% |
| Q1 FY2025 | Mar 31, 2025 | $411.00K | -82.8% |
| Q4 FY2024 | Dec 31, 2024 | $565.00K | -42.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.33M | +156.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.36M | -55.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.39M | +96.9% |
| Q4 FY2023 | Dec 31, 2023 | $982.00K | +80.2% |
| Q3 FY2023 | Sep 30, 2023 | $907.00K | +367.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.03M | +1904.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.22M | -32.8% |
| Q4 FY2022 | Dec 31, 2022 | $545.00K | +39.7% |
| Q3 FY2022 | Sep 30, 2022 | $194.00K | -30.2% |
| Q2 FY2022 | Jun 30, 2022 | $151.00K | -54.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.81M | +600.8% |
| Q4 FY2021 | Dec 31, 2021 | $390.00K | -19.4% |
| Q3 FY2021 | Sep 30, 2021 | $278.00K | -40.3% |
| Q2 FY2021 | Jun 30, 2021 | $328.00K | -73.1% |
| Q1 FY2021 | Mar 31, 2021 | $258.00K | -63.0% |
| Q4 FY2020 | Dec 31, 2020 | $484.00K | -87.4% |
| Q3 FY2020 | Sep 30, 2020 | $466.00K | -72.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.22M | -80.9% |
| Q1 FY2020 | Mar 31, 2020 | $697.00K | -93.2% |
| Q4 FY2019 | Dec 31, 2019 | $3.86M | +42.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.71M | -4.6% |
| Q2 FY2019 | Jun 30, 2019 | $6.39M | +70.3% |
| Q1 FY2019 | Mar 31, 2019 | $10.24M | +8.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.72M | -34.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.79M | -10.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.75M | +2203.1% |
| Q1 FY2018 | Mar 31, 2018 | $9.44M | +5057.9% |
| Q4 FY2017 | Dec 31, 2017 | $4.12M | +878.1% |
| Q3 FY2017 | Sep 30, 2017 | $2.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $163.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $183.00K | – |
| Q2 FY2016 | Jun 30, 2016 | $421.00K | – |
See a number that looks wrong?